

News Release

Contacts:

Patrick Gaffey
Executive Director, Corporate Communications
Sunovion Pharmaceuticals Inc.
508-787-4565
Patrick.Gaffey@sunovion.com

Jennifer Baird
Director, Corporate Communications
Sunovion Pharmaceuticals Inc.
(508) 787-4109
Jennifer.Baird@sunovion.com

Sunovion Celebrates Five-Year Anniversary Milestone

Company has contributed clinical advances and new treatment options, led advocacy and educational initiatives to address serious medical conditions

Marlborough, Mass., October 15, 2015 – [Sunovion Pharmaceuticals Inc.](#) (Sunovion) announced today that it is celebrating its five-year anniversary. Sunovion was established in October 2010 following the integration of Sepracor Inc. and Dainippon Sumitomo Pharma America, Inc., former U.S. operations of Sunovion's parent company Sumitomo Dainippon Pharma Co., Ltd. Over the course of five years, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.

“Since its inception in October 2010, Sunovion has focused on building its global infrastructure, throughout North America and Europe in particular, to broaden the availability of current and future medicines,” said Nobuhiko Tamura, Vice Chair and President, Sunovion Pharmaceuticals Inc. “Our goal is to continue to expand our global footprint and deepen relationships with the partners and communities

with whom we work to continue to provide innovation, meaningful advocacy, and relevant education towards the goals of improving lives and deepening the understanding of serious medical conditions.”

Over the past five years, Sunovion has reinforced its track record of bringing new Central Nervous System (CNS) therapies to market for people with serious medical conditions, including treatments to address schizophrenia, bipolar depression, and partial-onset seizures associated with epilepsy. During this time, the Company launched Latuda® (lurasidone HCl) and Aptiom® (eslicarbazepine acetate) in the U.S. and Canada, as well as LATUDA in Europe. Additionally, the company’s CNS pipeline includes potential therapies to address Attention Deficit Hyperactivity Disorder (ADHD) and neuropathic pain.

Sunovion has expanded its respiratory health portfolio, building on the heritage of Brovana® (arformoterol tartrate). The Company’s pipeline includes SUN-101 in development for the potential treatment of Chronic Obstructive Pulmonary Disease (COPD).

Sunovion’s key contributions during the past five years in research innovation, treatment access, and advocacy and community outreach include:

- Pioneering a unique approach to discovery in the CNS space based on a systems neurobiology platform that facilitates rapid clinical development;
- Actively supporting the introduction and passage of legislation for patient protection, and championing efforts to codify the six protected classes in Medicare Part D in the U.S.;
- Developing and supporting leading advocacy programs, working with national advocacy partners in the U.S. including the *Be Vocal: Speak Up for Mental Health*, *COPD Together*, and *Talk About It for Epilepsy!* initiatives. The company has also supported hundreds of other advocacy events held regionally in the U.S., as well as in the U.K. and Canada; and
- Hosting four annual *Hands On!* days of service, involving hundreds of employees donating thousands of volunteer hours to the local communities in which Sunovion employees live and work.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions. Sunovion’s track record of discovery, development

and commercialization of important therapies has included Brovana[®] (arformoterol tartrate), Latuda[®] (lurasidone HCl), and most recently Aptiom[®] (eslicarbazepine acetate).

Headquartered in Marlborough, Mass. Sunovion is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the Company's web sites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter [@Sunovion](https://twitter.com/Sunovion) and [LinkedIn](https://www.linkedin.com/company/sunovion).

LATUDA is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

APTIOM is used under license from BIAL.

BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc.

© 2015 Sunovion Pharmaceuticals Inc.